In the last trading session, 1.19 million shares of the Caribou Biosciences Inc (NASDAQ:CRBU) were traded, and its beta was 2.34. Most recently the company’s share price was $1.10, and it changed around $0.03 or 2.80% from the last close, which brings the market valuation of the company to $99.61M. CRBU currently trades at a discount to its 52-week high of $7.93, offering almost -620.91% off that amount. The share price’s 52-week low was $1.07, which indicates that the current value has risen by an impressive 2.73% since then.
Caribou Biosciences Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.44. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended CRBU as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Caribou Biosciences Inc is expected to report earnings per share of -0.42 for the current quarter.
Caribou Biosciences Inc (NASDAQ:CRBU) trade information
Instantly CRBU has showed a green trend with a performance of 2.80% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.2500 on recent trading dayincreased the stock’s daily price by 12.0%. The company’s shares are currently down -30.82% year-to-date, but still down -11.29% over the last five days. On the other hand, Caribou Biosciences Inc (NASDAQ:CRBU) is -23.08% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 63.33% from its current value. Analyst projections state that CRBU is forecast to be at a low of $3 and a high of $3.
Caribou Biosciences Inc (CRBU) estimates and forecasts
The year-over-year growth rate is expected to be -73.51%, down from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 1.84M in revenue for the current quarter. 2 analysts expect Caribou Biosciences Inc to make 2.75M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 3.56M and 2.43M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -48.20%. Forecasts for the next quarter put sales growth at 13.22%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -37.16%. Caribou Biosciences Inc earnings are expected to increase by -20.17% in 2025, but the outlook is negative -12.22% per year for the next five years.
CRBU Dividends
Caribou Biosciences Inc’s next quarterly earnings report is expected to be released in April.
VANGUARD GROUP INC, with 5.0891% or 4.54 million shares worth $7.45 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024 . The former held 2.77 shares worth $3.05 million, making up 3.06% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 2.29 shares worth around $2.52 million, which represents about 2.53% of the total shares outstanding.
